Lancet

Published by: Elsevier Science, Inc.  

People

  1. Norton
    Norton
  2. Motzer
    Motzer
  3. Sepkowitz
    Sepkowitz
  4. Tap
    Tap
  5. Kingham
    Kingham
  6. Robson
    Robson
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Offit
    Offit
  10. Rosa
    Rosa

Groups

  1. Department of Medicine (72)
  2. Solid Tumor Oncology Division (50)
  3. Surgery (23)
  4. Population Sciences Research Program (21)
  5. GSK Faculty (16)
  6. Breast Medicine Service (14)
  7. Genitourinary Oncology Service (14)
  8. Hematologic Malignancies, Division of (14)
  9. Center for Hematologic Malignancies (13)
  10. Survivorship Research (12)
Search Within
Formats
  1. Journal Article (142)
  2. Review (7)
  3. Correspondence (6)
  4. Editorial (6)
  5. Meeting Abstract (2)
Groups
  1. Department of Medicine (72)
  2. Solid Tumor Oncology Division (50)
  3. Surgery (23)
  4. Population Sciences Research Program (21)
  5. GSK Faculty (16)
  6. Breast Medicine Service (14)

More Groups

People
  1. Larry Norton (7)
  2. Robert Motzer (6)
  3. Kent Sepkowitz (5)
  4. Robert Wittes (5)
  5. Thomas Hakes (5)
  6. William Rosa (5)

More People

Years
  1. 2025 (3)
  2. 2024 (12)
  3. 2023 (14)
  4. 2022 (4)
  5. 2021 (8)
  6. 2020 (5)

More Years

Publishers
  1. Elsevier Science, Inc. (163)

Results (163)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Relieve the suffering: Palliative care for the next decade
    Editorial

    Rosa, W. E.; Connor, S.; Aggarwal, G.; Alsirafy, S.; Brennan, J.; Davies, H.; Downing, J.; Ferrell, B.; Harding, R.; Knaul, F. M.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S. L.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: A phase 1, first-in-human trial
    Journal Article

    Ghobadi, A.; Bachanova, V.; Patel, K.; Park, J. H.; Flinn, I.; Riedell, P. A.; Bachier, C.; Diefenbach, C. S.; Wong, C.; Bickers, C.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): An open-label, randomised clinical trial
    Journal Article

    Mowery, Y. M.; Ballman, K. V.; Hong, A. M.; Schuetze, S. M.; Wagner, A. J.; Monga, V.; Heise, R. S.; Attia, S.; Choy, E.; Burgess, M. A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study
    Journal Article

    Choueiri, T. K.; Albiges, L.; Barthélémy, P.; Iacovelli, R.; Emambux, S.; Molina-Cerrillo, J.; Garmezy, B.; Barata, P.; Basu, A.; Bourlon, M. T.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Spicer, J. D.; Garassino, M. C.; Wakelee, H.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C.; Majem, M.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Antimicrobial use at end of life: A missing link in public health discourse
    Correspondence

    Pandey, S.; Wisniewski, R.; Newman, T.; Seo, S. K.; Rosa, W. E.
    Lancet (2024)

    Fulltext@MSK | Save
  • (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial
    Journal Article

    Morris, M. J.; Castellano, D.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N.; Crosby, M.; Piulats, J. M.; Fléchon, A.; Wei, X. X.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Gelderblom, H.; Bhadri, V.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; López Pousa, A.; Abdul Razak, A.; Italiano, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • B-cell non-Hodgkin lymphomas
    Review

    Silkenstedt, E.; Salles, G.; Campo, E.; Dreyling, M.
    Lancet (2024)

    Fulltext@MSK | Save

    • Lancet – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 01406736 Unknown
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0140-6736 The Lancet Publishing Group
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0099-5355 The Lancet Publishing Group
    Lancet 1083-7159 Unknown
    Lancet 0099-5355 Unknown
    Lancet 0140-6736 Unknown
    Lancet 1474547X Unknown
    Lancet 1474-547X Elsevier Science, Inc.
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet 0140-6736 Elsevier Science, Inc.
    Lancet (North American Edition) 0140-6736 Unknown
    The Lancet 01406736 Elsevier Inc.
    The Lancet 0140-6736 Elsevier Science, Inc.
    The Lancet 01406736 1995
    The Lancet 1474547X Unknown
    The Lancet 01406736 Unknown
    The Lancet 01406736 1993
    The Lancet 0140-6736 Lancet United Kingdom
    The Lancet 01406736 1994
    The Lancet 01406736 Unknown
    The Lancet 0140-6736 Elsevier Inc.
    Unknown (0140-6736) 0140-6736 Unknown